RxDoctor Payments Data

Dominic Maffetone, MD

Family Medicine · Farmington, MINPI 1164950341

Payments from drug & device makers

$5,372in general payments, 2019–2025

Across 293 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$690
  • Johnson & Johnson$612
  • Pfizer$583
  • AstraZeneca$502
  • AbbVie$412
  • Lilly USA, LLC$336
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,365100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,372 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$57,414
Medicare patients
130
Services billed
831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$122,076
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$107,558
RybelsusSemaglutide42$92,859
TrulicityDulaglutide59$86,518
OzempicSemaglutide42$63,313
JanuviaSitagliptin Phosphate40$49,186
XareltoRivaroxaban38$45,529
ProliaDenosumab17$28,422
RexultiBrexpiprazole15$25,151
JardianceEmpagliflozin17$16,578
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$13,289
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,998
PaxlovidNirmatrelvir/Ritonavir21$10,916
Atorvastatin Calcium575$9,129
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$6,228

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$690$156,17284 claims
PfizerEliquis, Paxlovid$583$132,992117 claims
GSKTrelegy Ellipta$307$107,558114 claims
Lilly USA, LLCTrulicity$336$86,51859 claims
MerckJanuvia$86$49,18640 claims
Johnson & JohnsonXarelto$612$45,52938 claims
AmgenProlia$204$28,42217 claims
Otsuka America Pharmaceutical, Inc.Rexulti$238$25,15115 claims
Boehringer IngelheimJardiance$113$16,57817 claims
AstraZenecaBreztri Aerosphere$502$12,99815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Farmington

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →